At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.
AstraZeneca’s Saphnelo (anifrolumab-fnia) was approved in the United States for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
The World Health Organization recommended using arthritis drugs Actemra from Roche and Kevzara from Sanofi with corticosteroids for Covid-19 patients after data from some 11,000 patients showed they cut the risk of death.
AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
The U.S. Food and Drug Administration approved Kala Pharmaceuticals’ Eysuvis for the short-term treatment of dry eye disease.
Treating critically ill Covid-19 patients with corticosteroid drugs reduces the risk of death by 20 percent, an analysis of seven international trials found, prompting the World Health Organization to update its advice on treatment.
Incyte’s ruxolitinib cream hit the drug’s primary endpoint in the Phase III TRuE-AD2 trial of atopic dermatitis in adolescents and adults. Incyte and Eli Lilly announced topline results from the Phase III trial (FREEZE-AD4) of baricitinib in topical corticosteroids for the treatment of adults with moderate to severe atopic dermatitis who did not respond to treatment with cyclosporine.
AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.
Lexington, Mass.-based Aldeyra Therapeutics reported that the company’s reproxalap failed to meet primary or secondary endpoints in noninfectious anterior uveitis.
